^
    Back
    Association details:
    Biomarker:CLDN6 expression
    Cancer:Non Small Cell Lung Cancer
    Drug:AMG 794 (CD3 agonist, CLDN6 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    A Phase 1 Safety, Tolerability, and Pharmacokinetics Study of AMG 794 With Claudin 6-positive Non-small Cell Lung Cancer, Epithelial Ovarian Cancer, and Other Malignant Solid Tumor Indications

    Excerpt:
    ...- Participants with histologically or cytologically documented malignant solid tumor diseases expressing claudin-6 (CLDN6) including but...
    Trial ID:
    NCT05317078
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    AACR 2022
    Title:

    5202 - AMG 794, a Claudin 6-targeted half-life extended (HLE) bispecific T cell engager (BITE®) molecule for non-small cell lung cancer and epithelial ovarian cancer

    Published date:
    03/09/2022
    Excerpt:
    AMG 794 induces T cell activation and transient production of cytokines in co-cultures of T cells and CLDN6-expressing tumor cells….Weekly dosing of AMG 794 significantly inhibited the growth of established lung and ovarian xenograft tumors in immunocompromised mice injected with human T cells.